Finally, the combination of anti‐PD‐L1 + anti‐CTLA‐4 + CT did not show advantages over other CIT strategies in improving survival, but still exhibited OS superiority over CT alone in ES‐SCLC patients without LM. This evidence concerns the gene CD274 and small cell lung carcinoma.